ACES PHARMA
building blocks of life
building blocks of life
| Copyright © 2009 - 2020 ACES Pharma Inc. All rights reserved. |
 |  |  |  |  |
 | |  | |  | |  |
ACES is a leading provider for fully Integrated chemical and biological
services and products in the area of ANTIBODY DRUG CONJUGATE
(ADC). We are dedicated to offer numerous payloads/linkers products
and ADC conjugation services as well as in vitro and in vivo biological
assay. Our proprietary acestatins and acetecans ADC platforms are
composed of novel payloads (new versions of auristatins E, F and
dolastatin 10, SN38, Topotecan and Exatecan derivatives) with
cleavable and non-cleavable linkers. ADCs prepared from these
acestatins/acetecans demonstrated the same or improved efficacy and
safety profiles than ADCs from other known ADC platforms in vitro and
in vivo tumor models.
services and products in the area of ANTIBODY DRUG CONJUGATE
(ADC). We are dedicated to offer numerous payloads/linkers products
and ADC conjugation services as well as in vitro and in vivo biological
assay. Our proprietary acestatins and acetecans ADC platforms are
composed of novel payloads (new versions of auristatins E, F and
dolastatin 10, SN38, Topotecan and Exatecan derivatives) with
cleavable and non-cleavable linkers. ADCs prepared from these
acestatins/acetecans demonstrated the same or improved efficacy and
safety profiles than ADCs from other known ADC platforms in vitro and
in vivo tumor models.
ADC CORE TECHNOLOGY
Invent Novel Potent and Efficient Auristatin and
Dolastatin Payloads: Acestatins (Granted US patent)
Dolastatin Payloads: Acestatins (Granted US patent)
ADCs prepared from acestatins demonstrated the
same or improved efficacy and safety profiles than
ADCs from other auristatins and dolastatins in
vitro and in vivo tumor models.
Please click to read more.
same or improved efficacy and safety profiles than
ADCs from other auristatins and dolastatins in
vitro and in vivo tumor models.
Please click to read more.
INTEGRATED SERVICE PLATFORM
ADC Conjugation platform with new acestatin and acetecan warheads
and linkers: Conjugation of customer's antibodies with acestatin and acetecan warheads
(Mab-acestatins and Mab-acetecans)
ADC Conjugation platform with known warheads
and linkers
- MMAE type ADC (mAb-vc-MMAE)
- MMAF type ADC (mAb-mc-MMAF)
- Auristatin type ADC (mAb-vc-auristatin F, C-terminus)
- DM1-type ADC (mAb-SMCC-DM1)
- DM3-type ADC (mAb-L-DM3)
- DM4 type ADC (mAb-SPBD-DM4)
- DBCO-PEG-mertansine type ADC
- DBCO-L-payload -mAb
- Duocarmycin-L-mAb
- PBDs-type ADC (mAb-L-PBD)
- Mab-L-Topoisomerase inhibitors (SN-38, Topotecan, exatecans and other
campethecins)
ADC Conjugation kits: including DM1-SMCC, DM4-SMCC, DM4-SPBD, MC-vc-
MMAE, MC-MMAF, MC-vc-auristatin F(C-terminus), L-Duocarmycin, L-PBDs, MC-L-SN38,
MC-L-topotecan, MC-L-exatecans, etc
DBCO-PEG-vc-MMAE for Site-specific Conjugation of Antibody
____________________________________________________________________________________________________________________________________________________________
- MMAE, MMAF, auristatins E, F, and more
- MMAE-Linkers MMAF-linkers, and auristatin F-linkers
- Ansamitocin, maytansinol, and derivatives
- Maytansine-Linkers
- DM4, and DM4-linkers
- Duocarmycin-linkers
- PBD-linkers
- MC-L-topoisomerase inhibitors (MC-L-SN38, MC-L-exatecans
and others)
Xenograft tumor model assay
- DAR values (Drug-antibody ratios)
- HIC analysis (Hydrophobic ion chromatography)
- Elisa assay
- In vitro viability assay (IC50)
- In vivo Xenograft tumor model evaluation
- And more
Shelf Products on ADC: (from mg to grams in stock)
- MMAE, MMAF, auristatins E, F, and more
- MMAE-Linkers MMAF-linkers, and auristatin F-linkers
- Ansamitocin, maytansinol, and derivatives
- Maytansine-Linkers
- DM4, and DM4-linkers
- Duocarmycin-linkers
- PBD-linkers
- Govitecans (MC-L-SN38)
- Dxd(Exatecan derivatives)
- Deruxtecan
Flexible business model for licensing, partnership
and services...
and services...
Payloads, payloads-linkers, and demonstrated at
grams to hundreds of gram scales
grams to hundreds of gram scales
Custom Synthesis
Our proprietary acestatins are composed of
twelve novel payloads: new versions of auristatins
E ,F and dolastatin 10) with cleavable and non
cleavable linkers.
twelve novel payloads: new versions of auristatins
E ,F and dolastatin 10) with cleavable and non
cleavable linkers.
Invent Novel Efficient Acetecans ADC Platform
(Topoisomerase inhibitors/linkers ( patent pending)
(Topoisomerase inhibitors/linkers ( patent pending)